by The radiopharmaceuticals market size is poised to grow by USD 13.67 billion by 2032 from USD 5.2 billion in 2022, exhibiting a CAGR of 10.2% during the forecast period 2023-2032.
Key Takeaways
- North America led the market with the highest market share of 44% in 2022.
- Asia-Pacific is expected to expand at the fastest CAGR during the forecast period.
- By Radioisotopes, the technetium-99m segment has held the largest revenue share of 45% in 2022.
- By Radioisotopes, the Gallium-68 segment is anticipated to grow at a noteworthy CAGR of 13.1% during the projected period.
- By Application, the cancer segment generated more than 53% of revenue share in 2022.
- By Application, the cardiology segment is projected to expand at the fastest CAGR over the projected period.
- By Type, the diagnostic segment contributed more than 67% of revenue share in 2022.
- By Type, the therapeutics segment is estimated to grow at the fastest CAGR over the projected period.
- By End User, the hospitals and clinics segment registered over 52% of revenue share in 2022.
- By End User, the medical imaging centers segment is estimated to grow at a remarkable CAGR of 14.8% over the predicted period
The radiopharmaceuticals market is a dynamic and rapidly evolving sector within the healthcare industry. Radiopharmaceuticals are medicinal formulations that contain radioisotopes, and they play a crucial role in diagnostic and therapeutic applications. These compounds are used in nuclear medicine procedures, aiding in the diagnosis and treatment of various medical conditions, including cancer and cardiovascular diseases. The market has experienced significant growth in recent years, driven by advancements in medical imaging technologies and an increasing focus on personalized medicine.
Get a Sample Report: https://www.precedenceresearch.com/sample/3418
Radiopharmaceuticals Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 10.2% |
| Market Size in 2023 | USD 5.7 Billion |
| Market Size by 2032 | USD 13.67 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Radioisotope, By Application, By Type, and By End User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Parenteral Nutrition Market Size To Rake USD 11.62 Bn By 2032
The empirical study on the global Radiopharmaceuticals market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Radiopharmaceuticals Market. Our market report for the Radiopharmaceuticals market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Top Key Players:
- Amgen Inc.
- Eli Lilly and Company
- Novartis International AG
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- GlaxoSmithKline PLC
- Sanofi
- Johnson & Johnson
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Mylan N.V.
Radiopharmaceuticals Market Opportunities:
The radiopharmaceuticals market presents several exciting opportunities for growth and innovation. One key opportunity lies in the expanding applications of radiopharmaceuticals beyond traditional diagnostic imaging. Therapeutic radiopharmaceuticals, in particular, hold immense potential for treating various cancers by delivering targeted radiation to cancer cells. Additionally, the growing prevalence of chronic diseases, coupled with an aging population, creates a substantial market for diagnostic procedures involving radiopharmaceuticals. Advancements in radiopharmaceutical research and development, such as novel radioisotopes and imaging agents, further contribute to the expanding landscape of opportunities.
Radiopharmaceuticals Market Challenges:
Despite the promising outlook, the radiopharmaceuticals market is not without its challenges. Regulatory complexities and stringent approval processes pose obstacles to market players, slowing down the introduction of new products. Supply chain issues, especially concerning the production and distribution of radioisotopes, can also impact market growth. Moreover, concerns about radiation exposure and the need for specialized infrastructure for handling radiopharmaceuticals present challenges in widespread adoption. Market stakeholders need to address these challenges collaboratively to ensure the sustained growth and success of the radiopharmaceuticals market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Radiopharmaceuticals market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Market Segmentation:
By Drug Class
- Bisphosphonate
- Hormone Replacement Therapy
- Selective Estrogen Receptor Modulator (SERMs)
- RANK ligand (RANKL) Inhibitor
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Radiopharmaceuticals market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Radiopharmaceuticals market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Radiopharmaceuticals market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Radiopharmaceuticals market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Radiopharmaceuticals Market
5.1. COVID-19 Landscape: Radiopharmaceuticals Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Radiopharmaceuticals Market, By Radioisotope
8.1. Radiopharmaceuticals Market, by Radioisotope, 2023-2032
8.1.1. Iodine I
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Gallium 68
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Technetium 99m
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Fluorine 18
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Radiopharmaceuticals Market, By Application
9.1. Radiopharmaceuticals Market, by Application, 2023-2032
9.1.1. Cancer
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Cardiology
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Radiopharmaceuticals Market, By Type
10.1. Radiopharmaceuticals Market, by Type, 2023-2032
10.1.1. Diagnostic
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Therapeutic
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Radiopharmaceuticals Market, By End User
11.1. Radiopharmaceuticals Market, by End User, 2023-2032
11.1.1. Hospitals and clinics
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Medical Imaging centers
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Radiopharmaceuticals Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.1.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.3. Market Revenue and Forecast, by Type (2020-2032)
12.1.4. Market Revenue and Forecast, by End User (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Type (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End User (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.2.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.3. Market Revenue and Forecast, by Type (2020-2032)
12.2.4. Market Revenue and Forecast, by End User (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Type (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End User (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Type (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End User (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Type (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End User (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.3.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.3. Market Revenue and Forecast, by Type (2020-2032)
12.3.4. Market Revenue and Forecast, by End User (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Type (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End User (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Type (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End User (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Type (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End User (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.4.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.3. Market Revenue and Forecast, by Type (2020-2032)
12.4.4. Market Revenue and Forecast, by End User (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Type (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End User (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Type (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End User (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Type (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End User (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Type (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Radioisotope (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Type (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End User (2020-2032)
Chapter 13. Company Profiles
13.1. Bayer AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Iso-Tex Diagnostics, Inc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Jubilant Pharmova Limited
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Novartis AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. General Electric Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Lantheus Holdings, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Eli Lilly and Company
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Siemens AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Curium Pharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Cardinal Health Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
About Us:
Our team comprises a dedicated group of research analysts and management consultants who are driven by a unified vision: assisting individuals and organizations in realizing their strategic objectives, both immediate and long-term, through the provision of comprehensive research services. At Precedence Research, we have positioned ourselves to cater to the needs of a diverse range of entities, including established companies, startups, and non-profit organizations across various sectors. Our expertise extends to industries such as packaging, automotive, healthcare, chemicals and materials, industrial automation, consumer products, electronics and semiconductors, IT and telecommunications, and energy. With a wealth of experience within our ranks, our skilled analysts are equipped with extensive knowledge of the research landscape.
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
